Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.

Abstract

Biotechnology Law ReportVol. 41, No. 5 Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.United States Court of Appeals of the Federal Circuit, 2022 No. 2021-1495, 2022 WL 2525318 (non-precedential)Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMANEdited for Biotechnology Law Report by CHRISTOPHER M. HOLMANChristopher M. Holman is a Professor of Law at the University of Missouri–Kansas City School of Law; a Senior Scholar at the Center for the Protection of Intellectual Property at the Antonin Scalia Law School, George Mason University; and the Executive Editor of Biotechnology Law Report.*The synopsis is original content and the decision itself has been condensed for ease of readability.Search for more papers by this authorPublished Online:11 Oct 2022https://doi.org/10.1089/blr.2022.29284.cipAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 41Issue 5Oct 2022 InformationCopyright 2022, Mary Ann Liebert, Inc., publishersTo cite this article:Edited for Biotechnology Law Report by CHRISTOPHER M. HOLMAN.Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc..Biotechnology Law Report.Oct 2022.262-266.http://doi.org/10.1089/blr.2022.29284.cipPublished in Volume: 41 Issue 5: October 11, 2022Online Ahead of Print:September 23, 2022PDF download